UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 297

Sortiert nach

Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

Molecular therapy, 2013-05, Vol.21 (5), p.1096-1103

2013

Link zum Volltext

Verfügbarkeit prüfen

Advances in Medical Biochemistry, Genomics, Physiology, and Pathology

1, 2021

Link zum Volltext

Verfügbarkeit prüfen

A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme

Nanomedicine, 2015-02, Vol.11 (2), p.301-311

2015

Link zum Volltext

Verfügbarkeit prüfen

TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19

Viruses, 2022-03, Vol.14 (4), p.739

2022

Link zum Volltext

Verfügbarkeit prüfen

Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor

Oncoimmunology, 2018-10, Vol.7 (10), p.e1484982-e1484982

2018

Link zum Volltext

Verfügbarkeit prüfen

A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers

Molecular therapy, 2016-08, Vol.24 (8), p.1484-1491

2016

Link zum Volltext

Verfügbarkeit prüfen

Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system

Cancer research (Chicago, Ill.), 2007-04, Vol.67 (7), p.2938-2943

2007

Link zum Volltext

Verfügbarkeit prüfen

The Clinical Potential of Targeted Nanomedicine: Delivering to Cancer Stem-like Cells

Molecular therapy, 2014-02, Vol.22 (2), p.278-291

2014

Link zum Volltext

Verfügbarkeit prüfen

Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity

Cancers, 2022-10, Vol.14 (20), p.5092

2022

Link zum Volltext

Verfügbarkeit prüfen

A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models

Cells (Basel, Switzerland), 2022-10, Vol.11 (21), p.3434

2022

Link zum Volltext

Verfügbarkeit prüfen

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms

Oncoimmunology, 2018-07, Vol.7 (7), p.e1404216-e1404216

2018

Link zum Volltext

Verfügbarkeit prüfen

Effective treatment of glioblastoma requires crossing the blood–brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine

Biochemical and biophysical research communications, 2015-12, Vol.468 (3), p.485-489

2015

Link zum Volltext

Verfügbarkeit prüfen

Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma Cells In vitro and In vivo

Clinical cancer research, 2008-04, Vol.14 (7), p.2190-2198

2008

Link zum Volltext

Verfügbarkeit prüfen

Does a targeting ligand influence nanoparticle tumor localization or uptake?

Trends in biotechnology (Regular ed.), 2008-10, Vol.26 (10), p.552-558

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study

Molecular therapy, 2016-09, Vol.24 (9), p.1697-1706

2016

Link zum Volltext

Verfügbarkeit prüfen

Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma

Cancer letters, 2015-12, Vol.369 (1), p.250-258

2015

Link zum Volltext

Verfügbarkeit prüfen

Nanomedicine: Past, present and future – A global perspective

Biochemical and biophysical research communications, 2015-12, Vol.468 (3), p.511-517

2015

Link zum Volltext

Verfügbarkeit prüfen

A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma

International journal of cancer, 2019-11, Vol.145 (9), p.2535-2546

2019

Link zum Volltext

Verfügbarkeit prüfen

Nanoimmunoliposome delivery of superparamagnetic iron oxide markedly enhances targeting and uptake in human cancer cells in vitro and in vivo

Nanomedicine, 2008-12, Vol.4 (4), p.318-329

2008

Link zum Volltext

Verfügbarkeit prüfen

A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival

ACS nano, 2014-06, Vol.8 (6), p.5494-5514

2014

Link zum Volltext

Verfügbarkeit prüfen

Antisense therapeutics: from theory to clinical practice

Pharmacology & therapeutics (Oxford), 2003-07, Vol.99 (1), p.55-77

2003

Link zum Volltext

Verfügbarkeit prüfen

Targeted Delivery of Small Interfering RNA : Approaching Effective Cancer Therapies

Cancer research (Chicago, Ill.), 2008-03, Vol.68 (5), p.1247-1250

2008

Link zum Volltext

Verfügbarkeit prüfen

Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue

Molecular cancer therapeutics, 2008-03, Vol.7 (3), p.559-568

2008

Link zum Volltext

Verfügbarkeit prüfen

A Pralidoxime Nanocomplex Formulation Targeting Transferrin Receptors for Reactivation of Brain Acetylcholinesterase After Exposure of Mice to an Anticholinesterase Organophosphate

International journal of nanomedicine, 2024-01, Vol.19, p.307-326

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 297

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(249)
Mit Volltextzugriff
(269)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

Advances in Medical Biochemistry, Genomics, Physiology, and Pathology

A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme

TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19

Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer

Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor

A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers

Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system

The Clinical Potential of Targeted Nanomedicine: Delivering to Cancer Stem-like Cells

Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity

A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms

Effective treatment of glioblastoma requires crossing the blood–brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine

Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma Cells In vitro and In vivo

Does a targeting ligand influence nanoparticle tumor localization or uptake?

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study

Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma

Nanomedicine: Past, present and future – A global perspective

A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma

Nanoimmunoliposome delivery of superparamagnetic iron oxide markedly enhances targeting and uptake in human cancer cells in vitro and in vivo

A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival

Antisense therapeutics: from theory to clinical practice

Targeted Delivery of Small Interfering RNA : Approaching Effective Cancer Therapies

Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue

A Pralidoxime Nanocomplex Formulation Targeting Transferrin Receptors for Reactivation of Brain Acetylcholinesterase After Exposure of Mice to an Anticholinesterase Organophosphate

Suchergebnisse filtern